R. Bindra

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R Bindra, R. S. Bindra, Ranjit S Bindra, Ranjit Bindra, Ranjit S. Bindra
Publication record
263 papers · 8,577 citations · H-index 43

PAPERS

Genomic Characterization of Metastatic Pituitary Neuroendocrine Carcinoma (PITNET) in Two Cases
20260 citationsauthor #5
Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes
20260 citationsauthor #10
Abstract 2902: Systematic mapping of chemo-genomic interactions between DNA damaging agents and DNA damage repair genes with targeted CRISPR knockout screening
20250 citationsauthor #13
Abstract 6291: CellPyAbility: an integrated toolkit for high-throughput cell viability assays and automated analysis
20250 citationsauthor #3
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
20256 citationsauthor #21
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions
20252 citationsauthor #31
EXTH-105. Comparative analysis of the MGMT-sensitive interstrand crosslinking agent KL50 based on IDH status in MMR-proficient and -deficient gliomas
20250 citationsauthor #6
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
20258 citationsauthor #26
MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy
20250 citationsauthor #11
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models.
20250 citationsauthor #22
Abstract A100: Systemic targeting of therapeutic RNA into pancreatic tumors via an RNA-binding and cell-penetrating antibody
20250 citationsauthor #17
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
20250 citationsauthor #12
Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.
20250 citationsauthor #15
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.
20253 citationsauthor #24
Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma
20251 citationsauthor #2
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
20244 citationsauthor #10
EXTH-23. NEW DNA-CROSSLINKING CHEMOTHERAPY IS EFFECTIVE AGAINST POST-TEMOZOLOMIDE MISMATCH REPAIR-DEFICIENT PATIENT-DERIVED HYPERMUTANT GLIOMAS
20240 citationsauthor #8
Abstract 7123: Biomarker-targeted alkylator and DNA damage repair inhibitor combination for refractory and relapsed acute myeloid leukemia (AML)
20240 citationsauthor #8
Abstract 2866: NAPRTsilencing in rhabdomyosarcoma confers therapeutic vulnerabilities to NAD+depletion
20240 citationsauthor #10
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.
20244 citationsauthor #10
Abstract 7117: Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
20240 citationsauthor #11
712 Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma
20240 citationsauthor #6
Abstract 3086: NAPRT silencing in oncometabolite-producing cancers confers therapeutic vulnerabilities to NAD+ depletion
20240 citationsauthor #17
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
20244 citationsauthor #17
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
202411 citationsauthor #13
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions.
202415 citationsauthor #7
Abstract PR-01: Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody
20240 citationsauthor #13
Abstract A081 Biomarker-driven targeting of NAD metabolism in rhabdomyosarcoma
20240 citationsauthor #10
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
20246 citationsauthor #17
O6-Guanine Targeting Novel DNA Cross-Linker and ATR Inhibitor Combination for MGMT-Silenced IDH1/2 Mutant Acute Myeloid Leukemia
20240 citationsauthor #9
Abstract B051: PARG inhibition leads to the formation of toxic nuclear PARP1 aggregates
20230 citationsauthor #6
CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS
20233 citationsauthor #2
Abstract 1568: Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-/MMR- gliomas and glioblastoma
20231 citationsauthor #8
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma
202319 citationsauthor #18
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
20234 citationsauthor #14
PARG inhibition induces nuclear aggregation of PARylated PARP1
20234 citationsauthor #7
Abstract B069: Targeting vulnerabilities in double strand break repair in cancer with polymerase theta inhibitors
20230 citationsauthor #4
866 Preclinical Study of Pamiparib, a CNS Penetrant PARP Inhibitor, in IDH1/2 Mutated Gliomas
20230 citationsauthor #3
Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors
20230 citationsauthor #4
Abstract 1132: Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types
20230 citationsauthor #9
MODL-02. DEVELOPMENT OF RODENT GLIOBLASTOMA MODELS OF MGMT-MEDIATED TEMOZOLOMIDE RESISTANCE
20231 citationsauthor #5
Abstract B040: NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
20232 citationsauthor #23
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
202317 citationsauthor #14
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
20231 citationsauthor #6
Title. Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
20230 citationsauthor #19
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
20224 citationsauthor #5
Oncometabolites as Regulators of DNA Damage Response and Repair.
20226 citationsauthor #2
TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor.
202226 citationsauthor #14
Abstract 663: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody
20222 citationsauthor #8
Abstract 2970: Oncometabolites confer vulnerabilities in NAD biosynthesis via NAPRT gene silencing
20220 citationsauthor #3
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
202224 citationsauthor #7
Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
20223 citationsauthor #5
Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide
20227 citationsauthor #2
Mechanism-based design of agents that selectively target drug-resistant glioma
202280 citationsauthor #5
Abstract 294: Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
20220 citationsauthor #6
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy
20229 citationsauthor #17
Polymer nanocarriers for targeted local delivery of agents in treating brain tumors
20227 citationsauthor #2
In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2
202219 citationsauthor #16
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
202228 citationsauthor #8
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
2022162 citationsauthor #12
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
20225 citationsauthor #3
Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy
20222 citationsauthor #4
Intrathecal Delivery and its Applications in Leptomeningeal Disease.
202222 citationsauthor #2
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
202217 citationsauthor #4
Introduction: Progress Towards Genomically-directed Radiosensitization.
20221 citationsauthor #2
Abstract P059: Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
20210 citationsauthor #6
Abstract P055: Targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitor and low-dose alkylating chemotherapy
20210 citationsauthor #11
Abstract P258: CBX-12 (alphalexTM-exatecan) sensitizes tumors to immune checkpoint blockade in an antigen agnostic manner by immune activation
20211 citationsauthor #8
Abstract 1179: MSH2 is necessary for temozolomide-induced ATR activation in MGMT-methylated cancers
20210 citationsauthor #5
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance
2021135 citationsauthor #20
Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore
20213 citationsauthor #9
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
202125 citationsauthor #6
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
202126 citationsauthor #23
The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance.
202114 citationsauthor #3
Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy.
20214 citationsauthor #4
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
202132 citationsauthor #7
EXTH-60. PRECLINICAL STUDY OF PAMIPARIB, A CNS-PENETRANT PARP INHIBITOR, IN IDH1/2 MUTATED GLIOMAS
20210 citationsauthor #3
CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
20210 citationsauthor #2
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma
20218 citationsauthor #8
Correction to ‘Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity’
20211 citationsauthor #23
Abstract P135: Systemic targeting of a CNS tumor (medulloblastoma) using a novel cell-penetrating, nucleic acid binding, monoclonal antibody
20210 citationsauthor #5
CTNI-18. PHASE I AND PRELIMINARY PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB (BGB290) WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS
20214 citationsauthor #2
CBIO-28. IDENTIFYING THE ROLE OF MISMATCH REPAIR IN TEMOZOLOMIDE-INDUCED ATR ACTIVATION FOR MGMT-METHYLATED GLIOBLASTOMA MULTIFORME
20210 citationsauthor #4
CRISPR screening identifies novel PARP inhibitor classification based on
20211 citationsauthor #8
Title : Brain distribution of berzosertib : an ATR inhibitor for the treatment of glioblastoma
20212 citationsauthor #9
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
202141 citationsauthor #5
Decreased miR-24-3p potentiates DNA damage responses and increases susceptibility to COPD
20202 citationsauthor #13
Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
202028 citationsauthor #4
CBIO-14. ELUCIDATING THE MECHANISM OF TEMOZOLOMIDE-INDUCED ATR ACTIVATION IN MGMT-METHYLATED GLIOBLASTOMA MULTIFORME
20200 citationsauthor #4
Stereotactic Radiosurgery for Pediatric Arteriovenous Malformations: A Case Series Reflecting One Institution’s Experience With Treatment
20200 citationsauthor #4
Abstract 4134: Characterization of ATRX loss combined with IDH1 R132H mutation in gliomas
20200 citationsauthor #2
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
202045 citationsauthor #12
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
2020880 citationsauthor #8
Oncometabolites suppress DNA repair by disrupting local chromatin signaling
2020205 citationsauthor #12
Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
20201 citationsauthor #1
MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease
202030 citationsauthor #15
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma
20205 citationsauthor #10
Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
202027 citationsauthor #15
Abstract 1389: Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib
20202 citationsauthor #5
Targeted DNA Damage Repair CRISPR/Cas9 Knockout Screen Identifies Novel Classification of Poly-ADP Ribose Polymerase Inhibitors Based on Key Base Excision Repair Proteins
20201 citationsauthor #7

TIMELINE

1997 853 citations

2002 130 citations

2003 292 citations

2004 372 citations

2005 871 citations

2006 70 citations

2007 603 citations

2008 319 citations

2009 50 citations

2010 209 citations

2011 67 citations

2013 90 citations

2014 73 citations

2015 14 citations

2016 408 citations

2017 1,271 citations

2018 396 citations

2019 357 citations

2020 1,309 citations

2021 297 citations

2022 424 citations

2023 52 citations

2024 44 citations

2025 20 citations

2026 0 citations

Unknown 1 citations

R. Bindra

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT